STOCK TITAN

Amedisys Announces CEO Departure

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Amedisys (NASDAQ: AMED) announced on November 17, 2022, that President and CEO Chris Gerard has left the company. Paul Kusserow, former CEO, will take over as Chairman and CEO until a new leader is selected. The board expressed confidence in Kusserow's ability to drive profitable growth and innovation. The company is initiating an executive search for Gerard's replacement. Amedisys is a leading home healthcare provider, servicing over 445,000 patients annually with approximately 21,000 employees across 36 states.

Positive
  • Paul Kusserow's return as CEO may stabilize leadership and boost investor confidence.
  • Amedisys has a strong foundation with over 445,000 patients served annually and a significant employee base of 21,000.
Negative
  • The unexpected departure of Chris Gerard may signal instability in leadership.
  • The search for a new CEO introduces uncertainty about the company's strategic direction and future performance.

Paul Kusserow returns as Chairman and CEO

BATON ROUGE, La., Nov. 17, 2022 /PRNewswire/ -- Today, the Board of Directors of Amedisys, Inc. (NASDAQ: AMED) announced that President and Chief Executive Officer, Chris Gerard, will leave the company effective November 17, 2022.

Paul Kusserow, Chairman of the Board of Directors, will serve as Chairman and CEO until a replacement is hired. Paul served as the CEO of Amedisys for seven years until early 2022.

Amedisys announced that it will begin its executive search for a new CEO.

"We are confident that under Paul's leadership, Amedisys will continue to have a future of profitable growth, innovation, top quality and consistent performance. Paul's growth and innovative mindset is a critical and stabilizing force to the Company. His experience, along with his passion, make us confident that this will serve Amedisys well during this time," said Julie D. Klapstein, Lead Independent Director of Amedisys.

"I am looking forward to returning as CEO and building on the excellent foundation we have at Amedisys," Kusserow said. "We are going to continue to build upon the foundation that has made Amedisys the best home health company in the industry – all driven by our extraordinary group of caregivers and our relentless focus on providing the best care for our patients."

About Amedisys

Amedisys, Inc. (the "Company") is a leading healthcare at home company delivering personalized home health, hospice, personal care and high acuity care services. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care, inpatient hospital, palliative and skilled nursing facility ("SNF") care in their homes, recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, or hospice care at the end of life. More than 3,000 hospitals and 90,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. With approximately 21,000 employees in 547 care centers within 36 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 445,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

Forward-Looking Statements
When included in this press release, words like "believes," "belief," "expects," "strategy," "plans," "anticipates," "intends," "projects," "estimates," "may," "might," "will," "could," "would," "should" and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations; the impact of current and proposed federal, state and local vaccine mandates; staffing shortages driven by the competitive labor market; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in Medicare and other medical payment levels; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; competition in the healthcare industry; changes in the case mix of our patients, the episodic versus non-episodic mix of our payors or payment methodologies; changes in estimates and judgments associated with critical accounting policies; our ability to maintain or establish new patient referral sources; our ability to consistently provide high-quality care; our ability to attract and retain qualified personnel; our ability to keep our patients and employees safe; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to integrate, manage and keep our information systems secure; the impact of inflation; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Cision View original content:https://www.prnewswire.com/news-releases/amedisys-announces-ceo-departure-301682181.html

SOURCE Amedisys

FAQ

Who is the new CEO of Amedisys?

Paul Kusserow has returned as CEO of Amedisys effective November 17, 2022.

What happened to Chris Gerard at Amedisys?

Chris Gerard left his position as President and CEO of Amedisys on November 17, 2022.

How is Amedisys performing in the home health sector?

Amedisys serves over 445,000 patients annually, indicating a strong performance in the home health sector.

What is the significance of Paul Kusserow's leadership for Amedisys?

Paul Kusserow's return is expected to provide stability and foster profitable growth at Amedisys.

What is the stock symbol for Amedisys?

The stock symbol for Amedisys is AMED.

Amedisys Inc

NASDAQ:AMED

AMED Rankings

AMED Latest News

AMED Stock Data

2.75B
32.14M
2.38%
90.41%
6.66%
Medical Care Facilities
Services-home Health Care Services
Link
United States of America
BATON ROUGE